Ads
related to: Acute Myeloid Leukemia- About AML
What Is AML
AML Treatment
- Oral Treatment
That You Can Take At Home
Find Out More
- Treatment Safety
Possible Side Effects
Important Safety Info
- Download Patient Info
View Patient Assistance Resources
Register to Learn More
- View Patient Information
Download Patient Brochures
Learn More
- Register for More Info
Receive Patient Resources
Get Additional Support
- About AML
Search results
Acute myeloid leukemia discovery tackles drug-resi | Newswise
Newswise· 1 day agoIndiana University School of Medicine researchers and their collaborators have uncovered molecular...
Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia -...
Nature· 23 hours agoPRMT2 is a key regulator of inflammation in acute myeloid leukemia. PRMT2-deficient cells exhibit a pro-inflammatory profile associated with STAT3 activation.
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials...
Morningstar· 4 days agoFN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at ...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks via Yahoo Finance· 7 days agoShattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute ...
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology...
Digital Journal· 7 days agoTUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid
Why Is Bio-Path (BPTH) Stock Up 20% Today?
InvestorPlace· 7 days agoBio-Path (NASDAQ:BPTH) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen....
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
WKRN Nashville· 7 days agoThe oral presentation includes five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated ...
Treatment of Blood Cancers
Digital Journal· 3 days agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the ...
Blincyto Picks Up New BCP-ALL Indication
Medscape· 3 days agoThe agent is the first BiTE approved for consolidation regardless of MRD status.
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 7 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Ads
related to: Acute Myeloid Leukemia